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ABSTRACT 
 
Background: Cancer related cognitive changes (CRCC) (commonly known as 
“chemobrain” or “chemofog”) has been documented to impact an individual’s quality 
of life, including the ability to return to work after cancer related treatment. However, 
due to CRCC’s characteristics to present as ‘mild’ cognitive deficits, it remains a 
controversial and contended issue in the surrounding literature, being questioned for 
its clinical significance and physiological existence. This study  Multiple challenges 
impede the assessment of CRCC, including comorbidities of symptoms, and the lack 
of standardised assessment tools available. No gold standard for objective or 
subjective assessment of CRCC has been established to date. This study sought to 
investigate what instruments are currently available to measure CRCC in breast 
cancer patients, their psychometric properties and the impact this has on their clinical 
utility for health practitioners.  
 
Method: The replication of a scoping study (originally conducted in February 2013) 
was performed in order to identify potential instruments. Searches were completed in 
eight databases to: (a) identify any new literature from 2013 to 2016, (b) identify 
instruments that may have clinical utility for the use of practitioners and (c) extract 
evidence for validity and reliability of the identified measures.  
 
Results: Twenty-two studies were identified, with a total of four assessment tools 
potentially available for use with the breast cancer population. Results indicate a lack 
of consideration for psychometric properties when selecting an instrument for the 
assessment of CRCC in studies. Impacting clinician’s ability to identify issues 
relating to CRCC in a standardised way in people recovering from breast cancer, and 
thus develop evidence-based care plans.   
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The invisible malady: A critical review of the quality 
of instruments to measure cancer related cognitive 
changes (CRCC) in women with breast cancer. 
 
 
SECTION 1: LITERATURE REVIEW 
 
 
 
Introduction to topic 
 
In recent years, research attempting to address cancer related cognitive changes 
(CRCC) has become a complicated phenomenon throughout the literature. It is 
becoming commonly reported that cancer patients may experience cognitive changes 
during or post treatment. CRCC can be described as an invisible malady, as it may not 
present on face value to observers, but has grave impact on the quality of life (QoL) 
for many cancer survivors. This includes major implications for a person such as the 
potential to impact functional and psychosocial aspects of an individual’s life 
(Cooper, 1997; Hwang, Lokietz, Lozano, & Parke, 2015). Much of the cognitive 
dysfunction reported throughout the literature is labelled as ‘chemo fog’ or ‘chemo 
brain’ and has been suggested that these conditions are the result of chemotherapy 
treatments (Biglia et al., 2012a; Raffa & Tallarida, 2010).  
 
This has resulted in debates regarding both the causality as well as the extent of the 
experiences of people who claim to have CRCC (Wefel, Vardy, Ahles, & Schagen, 
2011). These debates exist throughout the range of disciplines involved – from 
genetic and bio-molecular studies, through to general practitioners views as well as 
evidence from qualitative studies on participant’s experiences of CRCC (Wefel et al., 
2011). Due to the contentious nature of these debates surrounding the causality and 
biological existence of CRCC, it has become important to be able to assess and 
measure the symptoms so that rehabilitation or management of interventions for this 
population can be considered.  
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In order to achieve quality services for clients during their rehabilitation, practitioners 
must strive to uphold clinical integrity through evidence-based practice (EBP). 
Quality assessment and evaluation not only aids the identification and determination 
of occupational performance issues for a person with CRCC, but also provide support 
for EBP and the efficacy of a practitioners practice (Willard, Crepeau, Cohn, & 
Schell, 2009).  However, as yet, there is not a gold standard objective or subjective 
assessment of CRCC (Asher & Myers, 2015).  
 
Current assessment options for addressing CRCC include: neuropsychological testing, 
neuroimaging and subjective assessments.  These assessments provide some 
information but create questionable evidence concerning what is ecologically valid to 
determine the potential impact of CRCC in an individual’s functioning in an every-
day setting (Lewis, Chapparo, Mackenzie, & Ranka, 2016; Newman & Campbell, 
2013; Zhao et al., 2013). While some assessments test cognitive aspects that may 
demonstrate the existence of CRCC, they do not determine how these changes impact 
on individual’s environmental, social and personal context.  
 
Multiple challenges impede the assessment of CRCC, including the frequent lack of 
opportunity to assess cognition pre-cancer treatment, the differences in the 
populations being studied and the lack of standardised assessment tools and 
neuropsychological test batteries available (Asher & Myers, 2015; Giffard, Lange, & 
Leger, 2015). Olson et al., (2016) has identified three main issues regarding the 
current approach to screening tools for the identification of CRCC: (1) the lack of 
congruence between perceived cognition decline and measurable declines in cognitive 
assessment scores; (2) the wide range of cognitive domains assessed and 
neurocognitive test batteries utilised, and (3) the need for specifically trained 
professional staff and the length of time required for a full cognitive assessment 
(Olson et al., 2011). These three issues create a number of complications in the 
consideration of an effective assessment tool for identifying CRCC.  
 
In order to further understand why the issues surrounding the assessment of CRCC 
exist, this study sought to narrow its scope through the selection of people with breast 
cancer (BC) as its primary population of interest. Individuals with BC form a large 
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proportion of the population for research in this area, with 20% to 35% of individuals 
with BC experiencing cognitive deficits (Asher and Myers, 2015). Individuals with 
BC are also a prime target population for this study as 60% of BC survivors are of 
working age (Oberst, Bradley, Gardiner, Schnk & Given, 2010), where CRCC may 
demonstrate a more ‘obvious’ impact on everyday function. Secondly, this study 
sought to explore the effects of CRCC in non-central nervous system (non-CNS) 
cancers, in order to understand the effects of cancer therapy on cognitive function 
when cancer itself is not the primary pathological cause.  
 
The following literature review aims to explore the issues identified above, and 
identifies potential avenues and considerations for current practitioners when seeking 
out appropriate assessment tools for the evaluation of CRCC. This project seeks to 
identify potential assessments and evaluate their quality in assessing mild cognitive 
deficits associated with CRCC.  
 
Search Strategies Used 
 
Seven online databases were searched including: Cochrane Libray, CINAHL, 
MEDLINE, PubMED, PsychInfo, Scopus and OT Seeker. These databases were 
searched using the following terms: “cancer” or “oncology” or “systemic malignan*” 
or “neoplasm*” or “cancer survivor” or “malignan*” AND “cancer treatment” or 
“chemo*” or “chemotherapy” or “chemotherapy treatment” or “drug therapy” AND 
“assessment” or “instrument” or “test batter*” or “evaluation” or “outcome 
measure*” or “cognitive measurement*” or “assessment tool” or “outcome 
assessment” or “self-assessment” or “objective assessment” or “subjective 
assessment” or “symptom assessment” or “gold standard assessment” and “chemo 
fog” or “chemo brain” or “cancer related cognitive change*” or “cognitive 
impairment*” or “cognitive dysfunction” or “cognition” (as keyword and subject 
heading) or “cognitive decline” or “meta-cognition” or “neurocognitive sequalae” or 
cognitive function”.   
 
The seven databases produced a high level of repetition. Further sources were 
obtained through scanning the references of relevant articles and searching the 
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university library using basic searches with the identified relevant terms. The search 
was limited by year from 2005 to current and only studies in English were used. 
Literature explicitly on: palliative care, chronic psychiatric or neurological conditions, 
dementia, delirium, amnesia, traumatic or substance related brain injury, or other 
chronic non-cancer diseases or childhood cancer, were excluded as these were not 
relevant to the scope of this review. This literature review sought to identify and 
include journals, books, conference proceedings, published and unpublished works 
throughout occupational therapy, allied health, medical, nursing, psychology and 
neuropsychology disciplines. 
 
As this review was conducted to inform a cross-sectional study exploring the current 
assessment strategies and effectiveness of assessments for CRCC, similar studies 
were sought out and one study was identified. This study provided a scoping review 
of the assessment tools available for assessing cognitive function in adults during or 
following chemotherapy (Olson et al., 2016). After analysis of the literature, it was 
deemed important to replicate this study, and provide an updated list on the 
assessment instruments available for identifying CRCC. The search for Olson et al., 
(2016) was updated in 2013, and it was noted how much interest in the topic had 
grown within the 3 years of the studies updated search. Olson et al., (2016) 
determined that a systematic review was not warranted for this subject. However, 
given the rising interest in the subject, it was determined that more information 
regarding the psychometric properties of assessment tools currently being used was 
needed in order to help guide research and practice in this area, and Olson’s study 
could provide the appropriate scaffolding to re-run the search, and focus in on a 
specific population.  
 
The Invisible Malady: Defining CRCC and determining its scope 
 
For the purpose of this research, the term cancer related cognitive changes (CRCC) is 
to be used to describe any cognitive changes experienced by a person with non-CNS 
cancer during or post treatment. This issue is complicated by mechanisms underlying 
cognitive changes in the oncology population, which have not been fully elucidated, 
as the experience of cancer as an illness can be individual and varied (Asher & Myers, 
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2015). Therefore attribution of chemotherapy being responsible for dysfunction is not 
yet confirmed. The unknown aetiology of the cognitive changes has caused 
controversial debates throughout the literature and has had repercussions for health 
professionals when determining appropriate assessments, treatment and intervention 
options for their patients (Meyers & Brown, 2006; Penfold, 1996).  
 
In order to address the negative effects of CRCC in non-central nervous system (non-
CNS) cancer patients, an understanding of the potential factors that may contribute to 
CRCC is needed (Wefel et al., 2011). This includes attempting to untangle the 
multiple potential factors contributing to changes in cognitive processing (Hess et al., 
2015). This will be approached through two theoretical models:  
 
1. The Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function presented by Hess and Insel (2007).  
2. The Occupational Performance Model Australia (OPMA)  
 
The Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function 
 
Hess and Insel (2007) developed a conceptual model with five themes to understand 
and synthesise the literature surrounding chemotherapy related changes in cognitive 
functioning. The five themes are as follows: conceptual definitions, antecedents, 
consequences, moderators and mediators. These themes are based on the theory of 
human thought and cognition based on Miller (1909) cited by Hess and Insel (2007). 
They are used to clarify the factors impacting on cognition during cancer treatment 
regimens and their aftermath (Hess & Insel, 2007).  The model was created on the 
assumption that health care professionals were in need of a ‘clear understanding’ 
(Hess and Insel, 2007, p.982) of the associated changes that may occur during 
chemotherapy. Hess and Insel (2007) identify that this model needs to be tested and 
refined prior to its use in the development and implementation of invention strategies. 
This model is also potentially limited by its theoretical base being over one hundred 
years old. However, this model provides a logical basis that incorporates all aspects 
contested in the surrounding literature regarding causality, mechanisms and agents. A 
diagram of this conceptual model can be found in figure 1.  
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Figure	I:	The	conceptual	model	of	chemotherapy‐related	
changes	in	cognitive	function	presented	by	Hess	and	Insel	
(2007) 
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 	
	
15
Occupational Performance Model Australia (OPMA)  
 
The OPMA identifies the influences of the biopsychosocial model of health on 
clinical decisions (Turpin, Iwama, 2011).  While it was originally designed for the 
occupational therapy profession, with occupation as its central concept, this 
theoretical model highlights the importance of considering the impact of mild 
cognitive deficits on day-to-day life. Considering that there is no definitive answer to 
the causal mechanisms of CRCC, this model allows for the consideration of further 
factors, as anticipated by Hess et al. (2015)’s conceptual model, including mediators, 
associated toxicities and moderators. These elements can be wholly viewed as 
environmental, social, psychological, over a period of time and can be identified 
through the OPMA (see figure 2). 
	
Figure	II:	The	occupational	performance	model	Australia	(OPMA)	presented	by	
Turpin	and	Iwama	(2011)	
	
While it is recognised that there are limitations to both of these models, research in 
this area remains controversial and multifaceted. These two theoretical models allow 
for the consideration of both the processes surrounding potential CRCC in patients as 
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well as other aspects of their lives that may be impacting their functional capacity. 
This will be explored further in the following sections. 
 
Cancer survivorship and impact on daily living 
Cancer is one of the major causes of illness in Australia, causing substantial impacts 
on the social and economic avenues of individual’s lives (AIHW, 2015). The 
Australian Institute of Welfare (AIHW, 2015) states that trends through research 
show that Australia is currently experiencing an increase in cancer incidence rates 
combined with a decrease in mortality rates. This is potentially due to recent changes 
in societal values (i.e. nutritional content and lifestyle choices) and an aging 
population (Rowe & Kahn, 1997).  Cancer and its treatment can result in major 
impacts to functional and psychosocial aspects of an individual’s life, leading to the 
exacerbation of symptoms such as cognitive deficits, fatigue, depression and anxiety. 
These symptoms may impact participation in meaningful occupations and an 
individual’s experience of their life roles throughout their daily lives (Cooper, 1997; 
Hwang et al., 2015).  
 
CRCC has been found to directly impact cancer survivors in their emotional state and 
their functional state. A study conducted by Myers (2013) identified commonalities in 
participant’s experiences of feeling distressed, anxious and embarrassed (among other 
feelings) which exacerbated family tensions and frustrations related to the inability to 
fully participate in social and work related activities. Myers (2013) also identified that 
cancer survivors often wished they had been given the information that CRCC may 
occur, and to be assessed before or after treatment as an acknowledgement of the 
existence of their perceived cognitive changes. 
 
Cancer treatment is known to have effects on executive functioning including 
memory, language and attention span. This may include experiencing word-finding 
difficulties, difficulty prioritising tasks, decision-making and response to surrounds 
(Asher & Myers, 2015; Biglia et al., 2012a; Von Ah et al., 2012). This has impact on 
a person’s engagement with daily and meaningful activities including potential 
difficulties in returning to work or ease of functioning in activities of daily living 
(Lewis et al., 2016; Penfold, 1996). Interestingly enough, it is suggested that cancer 
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survivors may not report the full extent to which they are impacted by cognitive 
dysfunction, as they feel ‘lucky’ to have survived the disease (Miller, 2012). This is of 
concern as questions can be raised about how health practitioners are dealing with the 
potential of cognitive changes in their patients (Becker, Henneghan, & Mikan, 2015; 
Beitat, 2015) and why this topic is a relatively recent one in the literature.  
 
One of the major complications of addressing the potential impact of cognitive 
changes for people with cancer is the unknown causality of the effects. As cancer 
varies so differently depending on the population group, location of cancer and 
appropriate treatment options (depending on the malignancy) a range of potential 
mechanisms to explain cognitive dysfunction exist. These may include contributing 
factors from the direct neurotoxic effects of therapy, oxidative damage and genetic 
disposition (Asher & Myers, 2015). This is further complicated by the consideration 
of confounders such as fatigue, insomnia, side effects from medication and hormonal 
changes commonly experienced during cancer treatment. These confounders may 
affect research about factors that are contributing to cognitive dysfunction, or may 
distort the magnitude of the relationship between cancer treatment and cognitive 
dysfunction.  
 
Cancer treatment may involve varying processes depending on the tumour type, what 
stage of the disease the tumour was treated in, concomitant treatments and medical 
comorbidities (Asher & Myers, 2015). The three most common treatment options 
include: chemotherapy, surgical intervention and radiotherapy.  Some research 
predicts that exposure to chemotherapy may cause delayed brain injury, where myelin 
has delayed damage and therefore causes functional consequences (as demonstrated 
in animal research) (Veramonti & Meyers, 2009). This is due to a delayed white 
matter injury caused by chemotherapy exposure, which Veramonti & Meyers (2009), 
report is consistent with clinical syndromes observed in cancer survivors.  
 
Declines in the capacity to learn and memory retrieval are reportedly the most 
common neuropsychological impairments faced by cancer survivors. These executive 
functions depend heavily on frontal subcortical networks, which are preferentially 
disrupted due to treatment. This includes treatment at both intracerebral and systemic 
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levels such as radiotherapy, chemotherapy, endogenous administration of cytokines 
and hormonal therapies (Veramonti & Meyers, 2009).  
 
There are many confounding factors including contextual features as well as 
biological changes that make identifying causal mechanisms complicated. McDonald 
and Saykin (2013) reviewed recent studies on understanding neural correlates of the 
effects of chemotherapy on breast cancer patients. They determined that structural 
abnormalities appear to relate to subjective and objective cognitive functioning, as 
well as biological factors that may help to elucidate symptoms. McDonald and Saykin 
(2013) suggest other confounding factors, such as a person’s background, stage of 
disease, menopausal status and chemo-induced amenorrhea (in breast cancer patients) 
and age. These factors are not only relevant to the population of breast-cancer 
patients, but can be relevant for all cancer populations.  
 
Further controversy exists in the literature regarding the time frames in which 
cognitive dysfunction is present in cancer patients. A systematic review by de Vries, 
Pullens, and Roukema (2010) report that cognitive dysfunction associated with 
treatment may resolve within one year, as opposed to reports from Schnipper (2001) 
who describe the potential of long term effects being life-long. To further complicate 
this temporal assessment of changes, multiple studies using pre-chemotherapy 
cognitive assessments show that some patients were experiencing cognitive changes 
prior to receiving treatment (Asher & Myers, 2015). These results highlight the 
variation of the experience of CRCC and the need for assessments relative to each 
individual who may experience CRCC.  
 
 Alibhai et al (2009) puts forward, in a critical review paper, the argument that there 
are few studies adequately powered to compare quality of life (QoL) symptoms with 
cancer type in long-term cancer survivors, and that only a minority of five-year 
survivors experience long-term and late effects. Alibhai’s study addressed survivors 
of long-term breast, prostate, colorectal and melanoma cancers. This is similar to a 
study conducted by Hwang et al (2015), revealing that cancer survivors experience 
cognitive disturbances primarily one year post cancer treatment. Results showed that 
cancer survivors experienced modest to moderate degrees of functional deficits in 
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areas of occupation, performance skills, body functions and psychosocial well-being, 
one year post treatment. They also reported lower perceived QoL during the first year 
post cancer treatment compared to before diagnosis, and after five years post 
treatment (Hwang et al., 2015).   
 
Little is known about the presentation of multiple concurrent symptoms. Fatigue, 
cognitive dysfunction and depression are commonly discussed in conjunction with 
each other, however little is known regarding the relationship between the three 
domains (Valentine & Meyers, 2001). Valentine and Meyers (2001) determine that 
this may be due to the subjective nature of symptoms, multiple potential causes and a 
lack of reliable assessment tools. Valentine and Meyers also suggest that a fuller 
understanding of the relationship between cognitive dysfunction and fatigue in cancer 
patients may benefit from studies of chronic fatigue syndrome and non-malignant 
diseases which also indicate cognitive impairment variations and mood disturbance as 
symptoms.  
 
Presence of CRCC in breast cancer patients 
Much of the current cognitive dysfunction research is being conducted on breast 
cancer patients with carcinoma tumours. Asher and Myers (2015) determine that 
several studies state that 20% to 35% of breast cancer patients have cognitive deficits, 
and this is in consideration to potential other confounding factors such as age, 
education and pre-treatment assessment. Asher and Myers (2015) examined cross-
sectional data that indicated 16% to 75% of patients experience cognitive dysfunction 
during chemotherapy treatment for breast cancer, compared to 4% to 11% of healthy 
controls. In light of the issue of potential cognitive deficits, these statistics make 
breast cancer patients a target population for this systematic review.  
 
This population was identified as a key population as 60% of breast cancer survivors 
are of working age (Oberst, Bradley, Gardiner, Schenk, & Given, 2010) and this 
group may suffer further cognitive induced difficulties in returning to work after 
breast cancer treatment (Lewis et al., 2016). Breast cancer patients have reported 
experiencing cognitive difficulties impacting their return to work and daily 
functioning, including difficulties in; reduced attention, memory, concentration, 
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multi-tasking, organising information and processing speed (Becker et al., 2015; 
Lewis et al., 2016; Player, Mackenzie, Willis, & Loh, 2014; Vardy et al., 2014). 
These findings allow the exploration of cognitive domains that need to be targeted 
when considering CRCC and the assessments available for identification of the 
cognitive changes in functional performance.  
 
Domains of cognition affected by CRCC in breast cancer 
 
CRCC has been determined as a subtle and domain specific phenomenon to occur 
after chemotherapy treatment (Biglia et al., 2012a; Jansen, Dodd, Miaskowski, 
Dowling, & Kramer, 2008; Meyers, 2000; Schagen, Boogerd, Muller, Dam, & 
Mellenbergh, 2006). These domains include: attention, mental flexibility, speed of 
information processing, visual memory and motor function (Biglia et al., 2012; 
Schagen et al., 1999). Biglia et al (2012) and Schagen et al., (1999, 2006) confirm in 
their studies that in objective assessment, these cognitive changes occur 
independently of emotional and psychological status. Biglia et al (2012) highlighted 
that self-perceived assessment of these changes showed correlations with depression 
and anxiety. However, these studies do not eliminate the long-standing debate 
regarding the existence of subtle cognitive changes.  
 
Current researchers are aware of the multitude of factors that may contribute to 
cognitive dysfunction and often account for this in their conclusions. Often, 
researchers avoid conclusive statements on the pathophysiology of CRCC.  
Confounding factors have made it difficult to translate this research to clinical 
applications, such as rehabilitation and intervention practices. There is need for a gold 
standard assessment tool for measuring the cognitive function of breast cancer 
patients to further this research, which can then contribute to the recovery of breast 
cancer patients. 
 
Cognitive domains and an information processing model 
 
For the purpose of this project, the cognitive domains identified above, in relation to 
the reports from breast cancer patients of cognitive change experiences, were 
examined through an adapted version of the ‘information processing model with 
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associated processing strategies’, presented by Nott (2008) (figure 3). While Nott’s 
adapted model was originally developed for examining agitation in traumatic brain 
injury patients, it was determined that the model was also appropriate for the 
examination of cognitive changes relevant to both (a) subtle changes and (b) domains 
identified as impacted by chemotherapy treatment.  
 
This model was developed through the analysis of the ‘Perceive, Recall, Plan and 
Perform (PRPP)’ system of task analysis (Chapparo, Ranka, & Occupational 
Performance, 1997). This system was used in a study by Lewis et al. (2016) who used 
the PRPP to determine how cognitive impairments experienced by breast cancer 
patients may impact occupational performance in complex work environments. This 
led to the consideration of appropriate assessment measures that could be utilised by 
occupational therapists working in an oncology setting. The model of ‘information 
processing model with associated processing strategies’ was found to be congruent 
with the categorisation of error types reportedly experienced by breast cancer patients.  
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Figure	III:	Information	processing	model	with	associated	processing	strategies	presented	
by	Nott	et	al.,	(2008)	
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Assessment tools  
General Background 
 
Currently there is no gold standard assessment tool to measure cognitive dysfunction 
in cancer patients (Asher & Myers, 2015). Research revolves around a distinction 
between subjective measures (including self-reports) and objective measures 
(including neuropsychological testing and neuroimaging). Assessment of cognitive 
dysfunction in cancer patients incorporates many challenges due to the multitude of 
symptom overlap with other disorders such as fatigue or depression, and the subtle 
nature of the symptoms. However, symptom overlap aside, determining the effects of 
cognitive dysfunction on cancer survivors is important in developing a therapeutic 
intervention care plan (Law, Baum, & Dunn, 2005; McGoey, Cowan, Rumrill, & 
Lavogue, 2010). Understanding of appropriate and best practice assessment tools and 
their clinical utility will guide practitioners in determining best clinical practice for 
their cancer survivors (Law et al., 2005; Wilkin, Hallam, & Doggett, 1992).  
 
For occupational therapists, the American Occupational Therapy Association (AOTA) 
affirmed that the use of occupation was essential to the evaluation and intervention of 
clients (AOTA, 2014). A client’s abilities must be measured through the proficient 
and appropriate use of instruments. The term ‘instruments’ will be used to allow the 
acknowledgment of a number of data collection methods such as interview, 
observation, or standardised test (Asher, 2007).  
 
Subjective versus objective assessment 
 
Research has identified that both subjective and objective assessments are susceptible 
to bias if not administered appropriately. This requires practitioners to not only assess 
the client, but to ensure assessment techniques utilised have strong psychometric 
properties including reliability, validity, sensitivity and specificity (Asher, 2007; Law 
et al., 2005; McGoey et al., 2010; Wilkin et al., 1992). Pullens and de Vries et al. 
(2010), through a systematic review, showed strong evidence for the lack of 
relationship between objective cognitive dysfunction and subjective cognitive 
dysfunction. They reported that the prevalence of subjective cognitive dysfunction 
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varied considerably during the assessment of subjective cognitive dysfunction. This 
may be the result of a variety of definitions, questionnaires and cut off scores 
(Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013), causing some 
disputes around the appropriateness of a non-standardised instrument in clinical 
practice. From an occupational therapy perspective, it is important to base 
assessments on ecological factors to determine a person’s function in their 
environment and according to their capabilities (Chapparo et al., 1997; Newman & 
Campbell, 2013).  
 
One aspect that cancer related outcome measures currently lack is the inability 
examine scores across instruments so that researchers are able to combine or compare 
results from one instrument to another (in regards to multiple studies) (Lipscomb, 
Gotay, & Snyder, 2005). This leaves practitioners with a great responsibility to select 
assessment instruments that have psychometrically strong properties in order to match 
their clinical objectives to the selected instrument. Practitioners must therefore have a 
clear purpose to the assessment they intend to use in clinical practice. Three forms of 
instruments with various purposes overarch the literature in consideration of clinical 
utility (Asher, 2007; Hinojosa, Kramer, & Crist, 2010):  
 
(1) Screening: the process of reviewing available data, observing a client, or 
administering screening instruments to identify an individual or 
population’s potential strengths and limitations and the need for further 
assessment. 
(2) Evaluation: Refers to the comprehensive process of obtaining and 
interpreting the data necessary to understand the individual, system or 
situation. Evaluation requires the synthesis of all data obtained, analytic 
interpretation of that data, reflective clinical reasoning and consideration 
of contextual factors. 
(3) Assessment: Refers to a specific tool, instrument or systematic interaction 
and is used to collect occupational profile information as part of the 
evaluation process. 
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The purpose of an assessment instrument is inherently linked with the careful 
application to the target population, and therefore the population needs to be defined 
(Larner, 2012). Larner (2012) identifies that prevalence rates of a health issue may 
differ between populations, and there are many contributing factors to the selection of 
an appropriate instrument. For instance, a person with breast cancer who feels ‘lucky’ 
to have survived cancer may not feel the need to attend a clinic for the identification 
of CRCC, compared to a person of the same diagnosis who had been warned in the 
early treatment process of the potential development of CRCC. Larner (2012) further 
identifies that there are risks and benefits to the screening process. Screening 
instruments should not be acknowledged as the equivalent of a diagnosis, but rather 
play a part in the clinical judgement that is to be made by health practitioners 
experienced in the diagnosis. Diagnosis remains the marked clinical and aetiological 
heterogeneity of a syndrome (Larner, 2012). This definition however, raises 
interesting concerns when considering the impact and assessment of CRCC in people 
with breast cancer.  
 
For the assessment of CRCC, Larner (2012)’s notion that screening remains separated 
from diagnosis, means that it becomes vital to acknowledge that assessment tools 
need to be psychometrically sound to support the judgement of the perceived 
symptoms. For instance, a practitioner needs to be confident in their selection of an 
instrument in order to present valid results. As CRCC may be considered ‘mild’, and 
controversies remain in the surrounding literature of its causality and aetiology, 
selection of an instrument for assessment relies heavily on the sensitivity and 
specificity of the intended instrument. Yet, the milder the symptoms, the risk of false 
positives and false negatives increases (Larner, 2012).  
 
Clinicians employ the concepts of sensitivity and specificity when considering 
diagnostic or screening tests to gold standard evaluations (Feuerman & Miller, 2008).  
Sensitivity refers to an instruments ability to detect change when change has occurred, 
yet remain stable when it hasn’t changed (i.e. ‘true positives’) (Larner, 2012; Resnik, 
2005). This property aims to ensure that early cases of a symptom will not be missed, 
but there is a risk of making false diagnoses. Specificity refers to the capacity of a test 
to obtain a negative test, when a symptom or condition is truly absent, i.e. true 
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negative (Larner, 2012; Portney & Watkins, 2014). This property aims to minimise 
incorrect diagnosis but could risk missing early cases. Specificity and sensitivity 
remain important when addressing assessment tools to measure CRCC due to the 
subtlety of the symptoms experienced by breast cancer patients.  
 
As identified, CRCC remains a difficult condition to assess due to the mild deficits 
experienced, residual the invisible malady. Therefore, clinicians assessing CRCC 
must maintain vigilance about the potential of ‘floor’ or ‘ceiling’ effects of 
assessment tools (Resnik, 2005). If an instrument lacks a sufficient scale range, there 
is the potential for participants to either score at the very top of the scale (‘ceiling’) or 
the very bottom (‘floor’) and therefore be unable to show change (Resnik, 2005). 
Assessment tools that are too general for the assessment of CRCC may not be 
sensitive or specific enough for its identification, and miss diagnoses or records of 
improvement for the individual, resulting in invalid assessment. Therefore, we 
propose to attempt to identify assessment tools that are potentially specific to the 
cognitive domains affected by CRCC in breast cancer patients.  
 
Selection of appropriate assessment tools  
 
A review of the literature has highlighted the lack of congruency in approaches to 
address the assessment of CRCC. A scoping review conducted by Olson et al. (2016) 
determined that a systematic review in this area was not warranted at this stage of 
research due to the variations in design, sample characteristics, stage of disease and 
measurement within the results of their literature search. However, the study provided 
a list of potential assessments relative to the cognitive domains affected in CRCC. It 
would be beneficial to repeat this study in order to update the assessment tool list (as 
the searches were completed in 2009 and 2013, 3 years before the publication of the 
article) and advance on the results by determining the rationale behind selected 
assessment tools in studies (i.e. psychometric property strengths and weaknesses).  
 
As demonstrated so far in this literature review, there is extensive literature on this 
topic and this has been increasing over the recent years (Wefel et al., 2011). 
Furthermore, it is important to understand the quality of assessment tools currently 
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available and the affects this has on clinical utility if an assessment protocol for 
CRCC is to be developed. This will assist in the identification of occupational 
performance issues as well as provide support for the pursuit of evidence based 
practice to improve rehabilitation practices, guide intervention and determine the 
efficacy of a clinicians practice (Willard et al., 2009). 
 
Due to the complexity or CRCC, we propose to focus on instruments that would be 
valuable to determining CRCC in the cognitive sub-domains identified earlier that are 
commonly experienced by people with breast cancer. These domains include: (1) 
attention/concentration, (2) memory (including working memory), (3) processing 
speed and (4) executive functioning. For the purpose of analysis, these domains have 
been placed into four domains, guided by the information-processing model with 
associated processing strategies presented by Nott et al., (2008).  
 
Therefore, this study will aim to determine the quality of assessment instruments 
currently available for measuring CRCC in women with breast cancer, and the impact 
this has on clinical utility. In doing so, an understanding of what instruments may be 
viable options for this population may be established, as well as highlight areas that 
practitioners should be aware of when selecting an assessment instrument to assess 
CRCC in cancer survivors. By understanding what psychometric properties are strong 
or weak for this population throughout the literature will help allow researchers and 
clinicians to potentially focus future research appropriately when considering the 
applicability of an instrument for the identification of CRCC.  
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ABSTRACT 
 
Purpose: The purpose of this critical review was to determine what assessment 
instruments are potentially available for identifying cancer related cognitive changes 
(CRCC) in women with breast cancer. It sought to determine valuable psychometric 
properties to be considered when approaching assessment tools for clinical use in this 
population.  
 
Methods: A replication of a scoping review (originally conducted in February 2013) 
was performed in order to identify potential instruments. Searches were completed in 
eight databases to: (a) identify any new literature from 2013 to 2016, (b) identify 
instruments that may have clinical utility for the use of practitioners and (c) extract 
evidence for psychometric properties of the identified measures. Critical analysis of 
both the studies and the instruments identified within the studies were undertaken in 
order to assess quality of research.  
 
Results: Twenty-two studies were identified, with a total of nineteen assessment 
instruments potentially available for use with the breast cancer population. Four 
instruments were identified as having the strongest psychometric properties and 
potential availability for current clinical utility.  
 
Conclusions: Results indicate a lack of consideration for psychometric properties 
when selecting an instrument for the assessment of CRCC in research studies. These 
results indicate that clinician’s ability to identify issues relating to CRCC in a 
standardised way is impacted. Thus, impeding the development of evidence-based 
care plans for individuals recovering from breast cancer.   
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The invisible malady: a critical review of the quality of 
instruments to measure cancer-related cognitive changes 
(CRCC) in women with breast cancer 
 
Key words: Breast cancer – psychological variables – outcome measure – critical 
appraisal 
 
Introduction 
	
The presence of cancer-related cognitive changes (CRCC) is becoming 
commonly recognised as a potential side effect of cancer treatment regimens 
throughout recent literature [1-4].  However, CRCC, (known colloquially as 
‘chemofog’ or ‘chemobrain’) remains a controversial phenomenon due to its 
characteristic presentation as a ‘mild’ deficit, therefore, raising questions about its 
clinical significance, and its causality or biological existence [5, 6]. Further to this, 
there remain multiple challenges that impede the assessment of CRCC including the 
lack of pre-cancer assessment information to establish a cognitive baseline, the 
differences in populations being studied, comorbidities of symptoms, and the lack of 
standardised assessment tools or neuropsychological test batteries available [6, 7].  
 
This has resulted in practitioners being unsure about how to approach the assessment 
of CRCC and therefore implement potential interventions and rehabilitation for their 
clients post cancer care [8]. The assessment of CRCC remains important despite the 
controversial research surrounding its causality. CRCC has been found to impact 
functional and psychosocial aspects of individual’s lives, including participation in 
meaningful activities (such as work and family interactions) as well as day-to-day 
roles [8-10]. As 60% of cancer survivors are of working age [11], the impact of 
CRCC on functional and psychosocial elements has the potential to be critical to work 
and family life for this population [11-13].  
 
It has been determined that 20%-35% of breast cancer patients experience CRCC, 
independent of their age, education, menopausal status and pre-treatment assessment, 
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and 16%-75% of breast	 cancer patients experience cognitive dysfunction during 
chemotherapy treatment compared to 4%-11% of healthy controls [6]. Biglia et al 
(2012) and Schagen et al., (2006) confirm through objective assessment, that 
cognitive changes experienced were independent of emotional and psychological 
status, as debated in the literature. Yet, despite the magnitude of literature in support 
of the existence and effects of CRCC, the multitude of factors that may impact on the 
assessment of cognitive change mean that there has been little progress on identifying 
appropriate assessment instruments. Confounding factors have made it difficult to 
translate this research into clinical applications for practitioners, especially on the 
issue of identifying appropriate assessment instruments [14].  
 
Currently no gold standard assessment tool exists in clinical practice for the 
identification of CRCC [6]. There is distinction between the use of subjective and 
objective measures, and both are contested due to the complexity of CRCC. This 
challenges practitioner’s ability to have a thorough understanding of the tools 
available, the risks of selection, determining appropriate evidence-based, and best 
clinical practice [15-18]. A literature review conducted to inform this research 
identified that because the presentation of CRCC to be subtle, psychometric 
properties including specificity, sensitivity and acknowledgement of floor and ceiling 
effects (as well as reliability and validity) are vital for an instrument to be valuable for 
the identification or assessment of CRCC.  
 
This study proposes to replicate and advance the scoping review performed by Karin 
Olson et al., (2016) in order to investigate the quality of research on current 
assessment tools available for the assessment of CRCC, and thus their clinical utility. 
CRCC is both subtle and domain specific [19-22]. The Olson et al., (2016) study 
concluded that a systematic review was not warranted due to variations in study 
design, sample characteristics, stage of disease and measurement found within their 
literature search. However, as more research is being published in this area, a 
duplicate search would be valuable to build on literature since 2013.   
 
Olson et al, have presented a comprehensive list of potential assessment instruments 
in the identification of CRCC.  However, a multitude of literature is evident on the 
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subject of CRCC and complicated by the complexity of differing cancers, treatment 
options and populations. Therefore, this study proposes to focus on the breast cancer 
population in order to examine instruments that would be valuable for the assessment 
of CRCC in the cognitive domains specific to the breast cancer population. These 
domains include: (1) attention/concentration, (2) memory, (3) processing speed and 
(4) executive functioning [3, 13, 23, 24]. Replicating Olson’s work, a rigorous critical 
appraisal of studies from 2013 to 2016 was conducted in relation to the breast cancer 
population.    
 
Methodology 
Search Strategy  
The search strategy was replicated from Olson et al (2016) with their permission.  The 
search strategy and methodology was based on the five-step method developed by 
Arksey and O’Malley (2005) for scoping reviews in order to map key concepts, 
identify the sources and types of available evidence [14, 25].  
 
A computerised search was performed with the assistance of a health science librarian 
on electronic databases. The University of Sydney’s library had access to different 
journals than the Olson et al (2016) study. Therefore the search strategy was adapted 
to the new databases, and conducted in the following databases available to the 
researchers: MEDline, CINAHL, Web of Science Core Collections, OT Seeker, 
Scopus and PsychInfo. The search strategy was then limited to identify articles 
published between January 2013 and 2016 (current) and had no language restrictions. 
The search was based on data-specific subject headings and searching syntax, as per 
Olson et al., (2016). Truncations were used on search terms that had alternative 
endings.  
 
Citations were then entered into Endnote to facilitate data management. Duplications 
were removed from the Endnote library before the commencement of the systematic 
screening process.  
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Screening Process 
The screening process took part in three stages: (1) title screen, (2) title and abstract 
screen and (3) full text screen. The initial screen (1) was completed by one researcher 
but when difficulties on a decision arose, such as determining whether the title 
indicated the study’s relevance, the second researcher was consulted. This was 
followed by a secondary screening (2), completed by two researchers, in order to 
reach consensus of potential full text articles to be considered. When a consensus as 
reached, two researchers read the full text articles (3) and selection of articles for 
inclusion in the review.  
 
Inclusion and Exclusion Criteria  
Studies were also considered against the inclusion criteria set by Olson et al (2016). 
This included: articles on the assessment of cognitive function in any adult population 
where eight cognitive domains were assessed. Studies were excluded if they were 
explicitly about individuals with chronic psychiatric or neurological conditions, 
dementia, delirium, amnesia, brain injury or other (non-cancer) chronic diseases [14]. 
This was rationalised in Olson’s study through the consideration of the challenges in 
assessing cognition in cancer patients differing from those encountered in other 
conditions and the specifics of cognitive change may be different in other groups due 
to overt changes related to pathology [14]. However, when studies where explicit 
about the four cognitive domains specific to breast cancer, consideration of them in 
the full text review was deemed appropriate, even if the study population was not 
specifically breast cancer.  
 
Studies were included in the initial two stages of the screening process if they met the 
following criteria: in English; directly about an instrument or tool to measure mild 
cognitive function (including subjective or objective testing); examined cognition that 
might have the potential to be relevant to CRCC in the breast cancer population; and 
examined at least one the four cognitive domains primarily effected in breast cancer 
patients.  Studies were excluded if they: were not in English, not related to cognitive 
tasks or functions, not related to the cancer population, were non-human studies, were 
orientated to a diagnosis other than cancer, or exclusively addressed older people aged 
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65 and over. An age range of between 18-65 years old were identified as the preferred 
population to represent effects on return to work as well as exclude any neurological 
conditions that may occur as a result of aging (i.e. dementia or Alzheimer’s) disease.   
 
Critical Appraisal of Articles and Psychometric Properties 
Two evaluations were conducted on the selected articles:  
 
(1) Critical appraisal evaluation form (Law and MacDermid, 2008) [ 
Studies were scored against a checklist, and could be rated scores of 0, 1 or 2 in line 
with the descriptors given (see Appendix II). Total scores were then calculated by 
adding the sum of the subtotals, dividing it by the highest possible score (high score = 
24) and multiplying it by 100 in order to acquire a percentage. Studies with a score 
higher than 60% were deemed eligible to be analysed in the second evaluation.  
 
(2) Quality criteria proposed for measurement properties of health status 
questionairres (Terwee, et al., 2007).  
If a study was eligible, as determined through the critical appraisal evaluation form, 
assessment instruments were identified from the studies and were put against the 
‘Terwee checklist’ (see Appendix III). Data regarding the psychometric properties for 
CRCC were independently extracted from the selected articles by two researchers to 
ensure methodological rigour. A measurement instrument needed to obtain positive 
ratings on the criteria of reliability, validity and responsiveness to be recommended 
for use in clinical practice. The Terwee checklist contained three dimensions of 
validity (content, criterion and construct), one dimension of reliability and, floor or 
ceiling effects.  
 
Final instruments potentially available for CRCC assessment  
A list of instruments potentially available for the identification of CRCC in the breast 
cancer population based on those utilised in the full text articles was collated. Articles 
were reassessed to determine whether sensitivity and specificity was acknowledged 
within the article.  
 
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 	
	
41
 
 
Results 
	
The search identified 11,889 articles published between 2013 and 2016, of which 
2,880 were removed, as they were duplicates. The remaining 9,726 were screened and 
filtered to identify potentially relevant articles (see Figure 4). A final 22 studies were 
identified and analysed by two researchers for critical appraisal (for appraisal 
guidelines). An overview of the final studies can be found in Table 1.  
 
Out of 22 studies, nine studies focused on breast cancer patients as their population 
[13, 28-35] and the remaining 13 were deemed appropriate for inclusion for analysis 
as they had a focus on mild cognitive impairment [36-48].  Out of the 9 studies with a 
population of breast cancer, 4 examined the use of particular assessment tools in 
cancer patients who may experience CRCC, [13, 30, 31, 33]; 5 studies examined the 
presence of CRCC, in which particular assessment tools were utilised for screening 
[28, 29, 32, 34, 35]; while the remaining studies analysed the psychometric properties 
of different assessment tools for mild cognitive impairment in a range of populations.
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Table I: Overview of studies and critical appraisal score  
Group	A:	Studies	focused	on	validation	of	assessment	instruments	in	breast	cancer	population	
	
Citation Geographical 
location and 
clinical setting 
Sample Characteristics Study 
Design 
Assessment 
instrument(s) 
identified 
Cognitive 
dimensions 
Results/Conclusions Score from 
Critical 
Appraisal 
[26] 
Cheung, 
Y. T., et 
al. (2013).  
[30] 
National Cancer 
Centre, 
Singapore,  
n=328 patients histologically diagnosed 
with breast cancer by a medical oncologist. 
Inclusion: at least 18 years old, were 
ambulatory in nature, spoke English or 
Chinese as their mother tongue. Exclusion: 
if breast cancer was a second malignancy, 
patients presented with evidence of brain 
metastases, psychosis, or any underlying 
neuropsychiatric illness that may impair 
their cognitive abilities.  
Prospective 
Study 
Functional 
Assessment of 
Cancer Therapy-
Cognitive (FACT-
Cog) 
Memory, verbal 
ability, concentration, 
mental acuity, 
functional 
interference, 
multitasking, 
noticeability, impact 
on QoL 
Results obtained from the concurrent validity analysis 
demonstrated that the English and Chinese FACT-
Cog total scores gas strong and moderate correlations. 
Results from known-group validity of the FACT-Cog 
were able to discriminate patients on the basis of their 
chemotherapy treatment status. Both versions of the 
FACT-Cog demonstrated satisfactory internal 
consistencies among cognitive domains, as well as 
factor analyses and item-to-domain correlations 
revealing that the majority of items in the FACT-Cog 
relate well to the constructs of their respective 
cognitive domains.  
58.34% 
Cook, S. 
A., et al. 
(2014). 
[31] 
Pre-treatment 
clinics, National 
Health Service 
Teaching 
Hospital 
n=229 patients. Inclusion: diagnosis of 
primary non-metastatic breast or prostate 
cancer. Exclusion: patients with recurrent 
or metastatic disease, or were considered 
by the clinical team or researcher to be too 
distressed or confused to give informed 
consent.  
Cross-
Sectional 
Metacognitions 
Questionnaire 30  
Cognition in general Confirmatory and exploratory factor analyses 
provided evidence supporting the validity of the 
previously published 5-factor structure of the 
Metacognitions Questionnaire 30. Specifically, both 
pre-treatment and 12 months later, this solution 
provided the best fit to the data and all items loaded 
on their expected factors. Structural equation 
modelling indicated that two dimensions of 
metacognition (positive and negative beliefs about 
worry) were significantly associated with anxiety and 
depression as predicted, providing further evidence of 
validity. 
66.67% 
Dorland, 
H. F., et 
al. (2016). 
[33] 
Netherlands  n=364 aged between 18-65 years. 
Inclusion: patients who had returned to 
paid work during or following cancer 
treatment in the last 3 months for at least 
12 hours per week, who had a history of 
paid work for at least 1 year prior to 
diagnosis. Exclusion: recurrent cancer 
diagnosis, treated for hospice care.  
Cross-
Sectional 
Cognitive 
Symptom 
Checklist-Work 
Working memory, 
executive function 
Exploratory factor analysis revealed two sub-scales, 
working memory and executive function. Results 
showed high internal consistency and reasonable 
construct validity for measuring work-specific 
cognitive symptoms.  
62.50% 
Lewis, J., 
et al. 
(2016).  
New South 
Wales, Australia 
n=10 women, aged between 39-67 years 
old at time of diagnosis of breast cancer. 
Inclusion: patients who were undergoing 
Cross-
Sectional, 
pilot study 
Percieve, Recall, 
Plan and Perform 
(PRPP) system of 
All dimensions. 
Administration time 
not specified.  
The 10 women experienced problems with work tasks 
that required cognitive strategies related to 
'programming', 'continuing' and 'attending' processing 
33.34% 
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[13] or had completed chemotherapy and 
represented working age population, had 
self-identified cognitive difficulties and 
were fluent in English. Exclusion: not 
specified.  
task analysis.  categories of the PRPP system, which represent 
different cognitive domains. Results indicated that 
participants demonstrated strengths in the capacity to 
evaluate their own thinking and performance. The 
PRPP identified as a potentially useful measurement 
and interview tool for the purpose of identifying the 
impact of mild cognitive impairments on function.  
	
 
 
Group B: Studies with BC patients as population but not explicitly validating assessment instrument 
	
Citation Geographical 
location and 
clinical setting 
Sample and inclusion/exclusion criteria Study 
Design 
Assessment instrument(s) 
identified 
Cognitive 
dimensions 
Results/Conclusions Score from 
Critical 
Appraisal 
[26] 
Berman, 
M. G., et 
al. (2014). 
[28] 
Comprehensive 
Cancer Centre. 
University of 
Michigan, United 
States 
n = 50 women with newly diagnosed (Stage 
0 to IIIa) breast cancer, and had completed 
primary surgical treatment with an 
established treatment plan for adjuvant 
chemotherapy or radiation therapy. 
Inclusion: intact cognitive function via Mini 
Mental Status Examination (MMSE) and 
absence of clinical depression via Patient 
Health Questionnaire (PHQ-8), right handed 
and met the magnetic resonance imaging 
screening criteria. Exclusion: if women had 
locally advanced or metastatic breast cancer 
(stage IIIb or higher), secondary diagnosis 
or a neurological or psychiatric condition, 
debilitating medical condition or taking 
psycho-active medication.    
Cross-
Sectional 
The attentional functional 
index (AFI); 
verbal working memory test 
(VWMT); 
fMRI 
Attention and 
working 
memory; 
administration 
time not 
specified.  
Results indicated that self-reported worry 
was significantly associated with objective 
performance on the verbal working memory 
test and perceived cognitive functioning in 
everyday life and that these relationships 
were present in both sample groups (pre-
chemotherapy vs. pre-radiation therapy) and 
stage of disease. fMRI imaging results 
showed a failure to deactivate default 
network regions and performance on 
cognitive tasks, associated with worse 
behavioural performance. 
41.67% 
Bernstein, 
L. J., et al. 
(2014). [29] 
The Princess 
Margaret Cancer 
Centre, Toronto, 
Ontario, Canada.  
n=65 patients, (n=28 controls) participants 
with breast cancer who had been treated 
with at least three courses of adjuvant (post-
surgery) or pre surgery) chemotherapy for 
breast cancer. Inclusion: women 60 years 
old or younger and fluent in English. 
Exclusion: participants with neurological 
injury such as stroke of other major illness, 
those with major pre-existing psychiatric 
history and those taking neuroleptic drugs.  
Cross-
Sectional 
Go-NoGo Task Attention 
(reaction 
time/alertness) 
Results indicated that some measures of 
stability of performance in attention 
appeared affected by breast cancer 
treatment, but only in limited conditions. 
Results supported the evidence for lapses in 
attention and lack of predictability in being 
able to perform tasks.  
50.00% 
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 	
	
45	
Deprez, S., 
et al. 
(2014).  
[32] 
Helsinki, Berlin n=18 patients scheduled to receive 
chemotherapy, n=16 patients who were not 
scheduled to receive chemotherapy and 
n=17 healthy controls. Exclusion: patients 
with menopause at the start of the study, 
previous history of psychiatric condition, 
previous cancer, any neurologic condition 
and use of psychotropic drugs. Longitudinal: 
baseline results occurred after pre-treatment 
surgery but before starting chemotherapy 
(t1: baseline), follow up for patients 
scheduled to receive chemotherapy was 
conducted 4-6 months after the end of 
treatment 
Longitudinal:  fMRI Attention, 
memory (multi-
tasking) 
Data from study provides evidence for 
decrease in brain activity during multi-
tasking after chemotherapy in breast cancer 
patients. This was not found in patients who 
did not receive chemotherapy or the healthy 
control sample. Data suggests that 
chemotherapy dampens brain activity during 
complex mental operations and this is 
related to cognitive complaints.  
41.67% 
Ganz, P. 
A., et al. 
(2013). [34] 
Los Angeles 
County Surveillance 
Epidemiology and 
End Results (SEER) 
registry, Los 
Angeles, United 
States.  
n=240 women, aged between 21-65 years, 
newly diagnosed with stage 0, I, II or  IIIA 
breast cancer. Inclusion: had completed 
primary breast cancer treatments within past 
3 months, had not yet started endocrine 
therapy, available for 12 month follow up 
and English language proficient. Exclusions: 
current or past disorder/disease of the 
central nervous system or medical condition 
impacting on cognitive function, head 
trauma history, epilepsy, dementia, learning 
disability, current or past psychotic-
spectrum disorder or current major affective 
disorder, daily alcohol or tobacco abuse, 
chronic illnesses, use of oral steroid 
medication and hormonal therapy.  
Cross-
Sectional 
Neuropsychological test 
battery: trailing making test 
(TMT) parts A and B, 
Stroop Interference Trial; 
Wechsler Adult Intelligence 
Scale, 3rd, Wechsler Test of 
Adult Reading (WTAR),  
All domains: 
administration 
time 120 
minutes 
Approximately one in five post-adjuvant 
treatment breast cancer patients had elevated 
memory and/or executive function 
complaints that were statistically significant 
associated with domain specific 
neuropsychological testing. Memory 
complaints were also deemed significantly 
significant with combined chemotherapy 
and radiation treatment. Results suggest that 
subjective cognitive complaints in part 
reflect objective neuropsychological 
performance, despite aetiology and biology 
appearing multifactorial.   
58.34% 
Jung, M. S. 
and B. 
Cimprich 
(2014).  
[35] 
University Cancer 
Centre, South 
Korea.  
n=64 total, n=32 women with breast cancer, 
n=32 healthy controls. Inclusion: enrolled 
four months after the last cycle of 
chemotherapy to assess the short-term 
treatment effect on cognitive function. 
Exclusion: all participants were screened 
with the Mini-Mental State Examination to 
exclude individuals with undiagnosed 
cognitive disorders such as dementia. 
Patients with pre-existing condition that 
may affect cognitive performance, such as 
mental, psychiatric, debilitating medical 
conditions and currently prescribed 
medication known to influence cognitive 
function.  
Cross-
sectional, 
comparative 
design.  
Digit span and controlled 
oral word association 
(COWA) and the attention 
network test (ANT) 
Attention, 
working memory 
The breast cancer group showed 
significantly higher occurrence of mild to 
moderate deficits in individual performance 
in attention and working memory, as 
compared to the healthy control group. 
Older age was significantly related to worse 
performance on cognitive rests, with the 
exception of error rates in the ANT 
(correlation coefficients ranging from 0.26 
to 0.58. The breast cancer group found to be 
a significant predictor of attention and 
working memory deficits.  
54.17% 
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Group C: Generalised assessment instruments for MCI  
 
Citation Geographical 
location and clinical 
setting 
Sample and inclusion/exclusion 
criteria 
Study 
Design 
Assessment instrument(s) 
identified 
Cognitive 
dimensions 
Results/Conclusions Score 
from 
Critical 
Appraisal 
[26] 
Armistead-
Jehle, P., et 
al. (2015). 
[36] 
Private outpatient 
practices, Edmonton, 
Alberta, Canada.  
Two samples consecutively tested: 
sample one n=1,917 cases, majority 
already receiving disability or 
compensation payments or were seeking 
such payments. Patients in sample one 
included conditions such as mild TBI, 
moderate to severe TBI, and 
neurological diseases. The second 
sample n=2,034 disability claimants 
with predominately non-neurological 
conditions who were recruited from a 
private practice. Sample two patients 
had primary non-mutually exclusive 
diagnoses including anxiety, depression 
and chronic pain.  
Cross-
Sectional 
Word Memory Test (WMT) Verbal episodic 
memory, memory.  
Results indicated significant correlations 
between the WMT and another memory 
evaluation instrument, the California 
Verbal Learning Test, indicating it's 
effectiveness as a measure of verbal 
memory.  
58.34% 
Bouman, Z., 
et al. (2016). 
[37] 
10 centres/hospitals 
across the 
Netherlands and 1 
university hospital in 
Belgium.  
n=235 patients who were administered 
the WMS-IV-NL as part of an extensive 
neuropsychological evaluation. N=182 
participants within the age range of 16-
69  (valued for our own study 
population). Mixed clinical sample was 
use including participants with TBI, 
neurocognitive impairment due to 
alcohol abuse, cerebral vascular 
accident, mild cognitive impairment, 
among other conditions. Exclusion: 
unable to speak/understand the Dutch 
language, or had a hearing or visual 
impairment making normal 
administration impossible.  
Cross-
Sectional 
Wechsler Memory Scale - 
Fourth Edition 
Immediate, delayed, 
auditory and visual 
memory indices.  
Results indicated that for adults (16-69 
years old) the 3-subtest short form was 
consistently more accurate (predictive 
accuracy ranged from 73% to 100%) than 
both 2-subtest short forms (range = 61%-
80%). Caution was warranted in the 
study when using the WMS-IV-NL 
Approach short forms to estimate all four 
indices.  
66.67% 
Cavaco, S., 
et al. (2013). 
[38] 
Mixed community 
sample, Portugal.  
n=1,038 community-dwelling 
Portuguese individuals. Inclusion: Older 
than 18 years of age, Portuguese as first 
language, lived in Portugal in the last 5 
years, had 3 years of education, and had 
done more than 50% of schooling in 
Portugal, absence of significant motor, 
Cross-
sectional, 
comparative 
design.  
Trail Making Test (TMT): 
Parts A and B - 
administration time not 
reported 
(A) attention, visual 
scanning, speed of 
hand-eye 
coordination and 
information 
processing; (B) 
working memory 
The TMT is able to undergo 
standardisation procedures in order to 
scale scores to adjust for an individual's 
demographic characteristics, and allows 
for the comparison between tests and 
individuals. The ratio and proportion 
scores are believed to be TMT's most 
41.67% 
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auditory or visual deficits after 
correction. Exclusion: history of 
developmental disorders, neurological 
disorder or moderate to severe 
psychopathology.  
and executive 
functions.  
sensitive indices for detecting 
impairments in executive functions, 
because they are less vulnerable to 
demographic characteristics.  
Cederfeldt, 
M., et al. 
(2015). [39] 
Regional Hospital, 
Sweden.  
n=17 patients. Inclusion: persons with 
mild stroke based on the criteria for 
stroke severity according to the National 
Institutes of Health Stroke Scale 
(NIHSS).  
Cross-
Sectional 
The Executive Function 
Performance Test (EFPT) 
Executive Function The inter-rater reliability for the EFPT 
was good. The median was 88% of the 
percentage agreement. No occasional 
disagreement was found between the 
raters, but there was a systematic 
disagreement in one out of 20 items. The 
translation and face validity process 
resulted in further clarification of the 
semantic and cultural equivalence of the 
EFPT, and the manual was changed 
accordingly. 
 58.34% 
Chan, E., et 
al. (2015).  
[40] 
Neuropsychology 
Department of the 
National Hospital for 
Neurology and 
Neurosurgery, 
London, United 
Kingdom 
n=55 patients with known focal frontal 
lesions, n=27 patients with focal non-
frontal lesions and n=70 healthy 
controls.  
Cross-
Sectional 
TMT Part B (TMT-B) Working memory 
and executive 
function 
Patients with frontal and non-frontal 
lesions performed significantly worse 
than healthy controls for both completion 
time and the number of errors. No 
significant difference for both completion 
time and the number of errors when 
patients with frontal and non-frontal 
lesions were compared. Performance was 
also not significantly different between 
patients with focal lesions within 
different regions of the frontal lobe 
(orbital, left lateral, right lateral, medial). 
Our findings suggest that the TMT-B is a 
robust test for detection of brain 
dysfunction. However, its capacity for 
detecting frontal executive dysfunction 
appears rather limited. Clinicians should 
be cautious when drawing conclusions 
from performance on the TMT-B alone 
37.50% 
Chaves, G. 
F. S., et al. 
(2016). [41] 
Institute of 
Psychiatry, 
Univeristy of Sao 
Paulo, Brazil 
n=58 elderly adults, middle income, 
community dwelling individuals from 
the hospital catchment area. Inclusion: 
age 65 years or older and MCI diagnosis 
according to the Petersen criteria.  
Cross-
Sectional 
The Canadian Occupational 
Performance Measure 
(COPM) 
Perceived cognitive 
changes.  
The COPM proved a valid and consistent 
instrument for evaluating ADL in elderly 
MCI patients. A total of 74.6% of the 
MCI patients reported difficulties in 
ADL. Of these problems, 41.2% involved 
self-care, 31.4% productivity and 27.4% 
leisure. This data further corroborates 
recent reports of possible functional 
impairment in complex ADL in MCI. 
 62.50% 
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Kostering, 
L., et al. 
(2015). [42] 
University of 
Freiburg, Germany 
n=29 total, between the ages of 19 and 
26 years old. All participants were 
recruited from undergraduate students at 
the University of Freiburg. Exclusion: 
current/past psychiatric or neurological 
disease, psychotropic medication and 
colour blindness.  
Cross-
Sectional 
Tower of London Planning 
Task (TOL-F) 
Executive 
functioning. 
Administration time 
not specified.  
The TOL-F planning accuracy has 
adequate absolute and relative test-retest 
reliability for experimental utility as it 
can be reliably used to measure of 
planning ability, in group based studies 
with individual participants, as important 
for clinical utility. Planning latencies 
should be used as complementary, but 
not sole measures of planning ability, 
especially in clinical settings.  
70.84% 
Lachman, 
M. E., et al. 
(2014). [43] 
United States of 
America 
n=4,268, aged between 32 and 84 years 
old. Participants represented a national 
sample, obtained from the study of 
Midlife in the United States (MIDUS). 
No inclusion or exclusion criteria 
identified.  
Longitudinal Brief Test of Adult 
Cognition by Telephone 
(BTACT) 
Episodic memory, 
working memory, 
reasoning, verbal 
fluency, and 
executive function. 
Administration time 
approximately 
20minutes.  
Study findings indicate good evidence for 
construct validity with a subsample tested 
in person. Results indicate that the 
BTACT can be used as an efficient, 
reliable and valid assessment of key adult 
cognitive dimensions in diverse samples 
with a wide range of age and socio-
economic status. Convergent correlations 
show BTACT comparison with gold 
standard cognitive tests administered in 
person. BTACT may be more sensitive 
than cognitive tests used to screen 
dementia. Results suggest that the 
BTACT may offer an efficient tool for 
clinicians and researchers to understand 
the processes of cognitive change over 
time in relation to health and disease.  
 62.50% 
Lassiter, K. 
S., et al. 
(2015).  [44] 
United States of 
America. Specific 
location not given.  
n=70 adult college students, age range 
from 21 - 54. Inclusion and exclusion 
criteria not specified.  
Cross-
Sectional 
General Abilities Measure 
for Adults 
Phonemic 
Awareness, Working 
Memory, Broad 
Attention, Cognitive 
Fluency, and 
Executive Processes 
Results indicated that GAMA IQ scores 
showed a moderately strong and 
statistically significant relationship with 
WJ-III COG General Intellectual Ability 
(r = 0.48), Cognitive Efficiency (r = 
0.45), Working Memory (r = 0.44), Fluid 
Reasoning (r = 0.34), and Processing 
Speed (r = 0.38) composites. Weaker 
correlations emerged between scores on 
the GAMA and WJ-III COG 
Comprehension-Knowledge (r = 0.28) 
and Visual-Spatial Thinking (r = 0.26) 
composites. Validity evidence did not 
support previous research that suggested 
the GAMA was a measure of Fluid 
reasoning abilities as opposed to 
crystalized reasoning abilities. While 
GAMA IQ scores were associated with 
41.67% 
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several broad cognitive abilities, 
including tests that measure executive 
functions, GAMA IQ scores over-
estimated WJ-III General Intellectual 
Ability scores for many adults. 
Lenehan, 
M. E., et al. 
(2016). [45] 
Hobart, Tasmania, 
Australia.  
n=500 adults between the ages of 49-79 
years old at the time of recruitment into 
the Tasmanian healthy brain project. 
Exclusion: participants who presented 
with a medical, neurological or 
psychiatric disorder that could 
potentially influence performance and 
participants with moderately elevated 
anxiety or depression symptoms.  
Cross-
Sectional 
Cambridge 
Neuropsychological Test 
Automated Battery 
(CANTAB) 
 
Episodic memory, 
working memory, 
executive 
functioning, 
planning, attention, 
semantic/verbal 
memory, decision 
making and response 
control.  
CANTAB tests may lack the sensitivity 
to measure discrete cognitive functions in 
healthy populations or may measure 
other cognitive domains not included in 
traditional neuropsychological test 
battery. Confirmatory factor analysis 
identified four factors: processing speed, 
verbal ability, episodic memory and 
working memory. However, CANTAB 
tests did not consistently load onto 
cognitive domain factors derived from 
traditional measures of the same 
function.  
 50.00% 
Morrison, 
G. E., et al. 
(2015). [46] 
International sample, 
representing multiple 
countries 
n=130,140 healthy volunteers obtained 
through Luminosity subscribers who 
took NeuroCognitive Performance Test 
(NCPT) as part of their used experience. 
Age range was 13 to 89 years of age, 
who reported were generally healthy 
and had taken NCPT previously. 
Clinical conditions were assessed on 
initial self-report survey and placed into 
non-normative sample. n=35,779 users 
completed follow up.   
Cross-
Sectional 
NeuroCognitive 
Performance Test (NCPT): 
subtests included Trail 
Making Tests (TMT) A and 
B, BACS Symbol Coding 
(MATRICS), Wechsler 
Memory Scale (WMS-III) 
and Forward and Reverse 
Spatial Span Board 
(MATRICS).  
Mental flexibility, 
memory, attention 
and speed of 
processing: 
administration time 
not specified.  
The eight NCPT subtests group into 4 
putative cognitive domains, have 
adequate to good test-retest reliability 
and are sensitive to selected age, 
education-related cognitive effects. It is 
proposed that this instrument could 
differentiate those who self-reported mild 
cognitive impairment from matched 
healthy controls. Instrument may have 
potential utility in clinical and research 
settings.  
 58.34% 
Morrison, 
M., et al. 
(2013). [47] 
Acute neurology 
stroke service, 
University-affiliated 
tertiary care hospital, 
Uniter States of 
America.  
n=25 participants, 6mo post-CVA and 
21 matched control participants. 
Inclusion: patients with first time 
ischemic stroke with scores of less that 
5 on the National Institutes of Health 
Stroke Scale. Exclusion: history of prior 
CVA, depression, dementia, psychosis 
or premorbid functional impairment.  
Cross-
Sectional 
Multiple Errands Test-
Revised (MET-R) 
Executive function Participants with mild cerebral vascular 
accident showed no to minimal 
impairment on measures of executive 
function at hospital discharge but 
reported difficulty with community 
integration at six months. The MET-R 
discriminated between participants with 
and without mild cerebrovascular 
accident (p<0.02). The Met-R was found 
to be a valid and reliable measure of 
executive functions appropriate for the 
evaluation of clients with mild executive 
function deficits who need occupational 
therapy to full participate in the 
community living.  
 70.84% 
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Nair, A. K., 
et al. (2016).  
[48] 
Helsinki, Berlin n=18 between age range of 27-59 years 
old. All participants were right handed, 
non-smokers. N=14 participants were 
healthy without any medication and four 
were understandable medication for 
hypertension and diabetes. Participants 
had refrained from caffeinated 
beverages for at least 4 hours prior to 
the recording.  
Cross-
Sectional 
Assessing Neurocognitive 
via Gamified Experimental 
Logic (ANGEL) 
Perception, memory, 
attention and 
decision making. 
Length of 
administration time 
not specified.  
Study demonstrates that ANGEL 
approach is able to simultaneously elicit 
multiple event related potentials in a 
significantly reduced time frame, elicit 
multiple event related potentials and is 
ecologically valid as it is representative 
of real-world task performance. Provides 
an opportunity to evaluate influences and 
is user friendly (to both user and 
administrator).  
41.67% 
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Results from the critical appraisal  
All 22 studies underwent critical appraisal of their assessment and study of 
psychometric properties. Four studies focused on the validation of assessment tools 
based on psychometric properties in the breast cancer population [13, 30, 31, 33] 
(group A: mean score = 55.21%); five studies assessed CRCC in cancer subjects, 
however focus of the study was not psychometric properties of tools but rather the 
detection of CRCC [28, 29, 32, 34, 49] (group B: mean score = 49.16%). The final 
group of studies assessed generalised assessment tools based on psychometric 
properties for mild cognitive impairment in non-cancer patients (group C: mean score 
= 55.45%).  
 
The five studies examining the presence of CRCC rather than specific assessment 
tools in group C did not perform as well in the critical analysis compared to the other 
studies. Overall, studies demonstrated consistent weaknesses in identifying specific 
psychometric hypotheses, considering an appropriate scope of psychometric 
properties, using an appropriate sample size, information about appropriate retention 
and follow-up, and appropriate analyses beyond reporting the point estimates.    
 
Results from Terwee Analysis  
Assessment tools identified in groups A and B were analysed using the original study 
article to specifically evaluate the psychometric properties. None of the assessment 
tools identified in group C contained information on the psychometric properties of 
the tools. Therefore to complete the Terwee analysis for this group, references cited 
on psychometric properties for each tool were examined. Results can be found in 
Table II, III and IV. 
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Table	II:	Group	A	‐	studies	focused	on	on	validation	of	assessment	instruments	in	breast	cancer	population	
Questionnaire Content validity Internal consistency Criterion validity Construct validity 
Reproducibility 
Responsiveness Floor/ ceiling effect Interpretability 
Agreement Reliability 
PRPP1 + 0 0 0 0 ? 0 ? + 
FACT-Cog2 + + ? + - + - ? +
MCQ-303 0 + 0 + + ? 0 ? +
CSC-W214 + + ? + ? + ? + 0
1 Perceive Recall Plan and Perform System of Task Analysis (PRPP) 
2 Functional Assessment of Cancer Therapy – Cognitive (FACT-COG) 
3 Metacognitions Questionnaire 30 (MCQ-30)  
4 Cognitive Symptom Checklist-Work (CSC-W21) 
 
Table III: Group B - Studies with BC patients as their population but not explicitly validating assessment instrument 
Questionnaire Content validity Internal consistency Criterion validity Construct validity 
Reproducibility 
Responsiveness Floor/ ceiling effect Interpretability Reference 
Agreement Reliability 
AFI55 + + ? + + + 0 ? + [50] 
* TMT-AB6 + ? 0 + ? 0 + ? + [51] 
*WMS-III7 + + 0 - 0 + - ? ? [52] 
ANT8 + ? ? + ? - ? ? - [53] 
Go-NoGo9 No adequate reference or study found in reference list related to CRCC or MCI - 
*BVMT-R10 No adequate reference or study found in reference list related to CRCC or MCI - 
VWMT11 No adequate reference or study found in reference list related to CRCC or MCI - 
*Stroop test12 Unable to obtain material referenced in study.  - 
DST13 No adequate reference or study found in reference list related to CRCC or MCI - 
COWA14 No adequate reference or study found in reference list related to CRCC or MCI - 
* Assessment tool part of a neuropsychological test battery 
 5 Attentional Functional Index (AFI)  
6 Trail Making Test – Parts A and B (TMT-AB) 
7 Wechsler Memory Scale (WMS-III) 
8 The Attentional Network Test (ANT)  
9 Conner’s Continuous Performance Test (Go-NoGo) 
10 Brief Visuospatial Memory Test (BVMT-R) 
+ = positive rating; 0 = indeterminate rating; - = negative rating; ? = no information available 
+ = positive rating; 0 = indeterminate rating; - = negative rating; ? = no information available 
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11 Verbal Working Memory Test (VWMT) 
12 Stroop Colour and Word Test (Stroop test) 
13 Digit Span Test (DST) 
14 Controlled Oral Word Association (COWA) 
 
 
Table IV: Group C - Generalised assessment instruments for CRCC 
Questionnaire Content validity Internal consistency 
Criterion 
validity 
Construct 
validity 
Reproducibility 
Responsiveness 
Floor/ 
ceiling 
effect 
Interpretability Agreement Reliability 
COPM15 + ? ? + ? 0 0 0 ? 
TOL-F16 + 0 0 ? + - - ? + 
BTACT17 + ? + + ? 0 0 ? + 
MET-R18 + ? 0 + ? 0 0 ? + 
WMS-IV-NL19 + + 0 - 0 + - ? ? 
15 Canadian Occupational Performance Measure (COPM) 
16 Tower of London Planning Task (TOL-F) 
17 Brief Test of Adult Cognition by Telephone (BTACT) 
18 Multiple Errands Test – Revised (MET-R) 
19 Wechsler Memory Scale – Fourth Edition (WMS-IV-NL)
+ = positive rating; 0 = indeterminate rating; - = negative rating; ? = no information available 
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Instruments with three or more psychometric properties identified by the 
Terwee checklist 
	
Four instruments were identified with the highest level of psychometric properties as 
identified by the Terwee analysis.  Additional information relating to sensitivity and 
specificity were sought for these instrument. An overview of these four instruments is 
presented in table 5, with a summary of the cognitive domains that the tools address.  
 
Table V: Instruments identified - three or more appropriate psychometric properties 
Instrument Content validity 
Criterion 
validity 
Construct 
validity Reliability 
Floor 
or 
ceiling 
effects 
Sensitivity Specificity 
Cognitive 
Domains 
Addressed 
FACT-
Cog + + + + ? ? ? 
Attention, 
memory, 
executive 
function 
CSC-W21 + ? + + + ? ? 
Working  
memory, 
executive 
funtioning 
BTACT + + + 0 ? ? ?  
AFI + ? + + ? ? ? 
Attention, 
working 
memory 
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Discussion 
Comparison with original Olson study  
This review identified 22 studies that were potentially relevant to understanding the 
assessment instruments available to assess CRCC, but only four were relevant to 
breast cancer patients. The original Olson et al., [14] study identified eleven studies in 
their scoping review between the years 1980 to 2013. The 22 additional studies since 
2013 confirm the rapid and growing interest in this area of practice. However, there is 
also an increasing need to ensure the quality of research that evaluates the 
psychometric properties of new and existing assessment instruments. This is 
especially relevant when selecting assessment tools for the population who experience 
CRCC. Only four assessment tools were identified in this study that were also 
identified in the Olson et al., (2016) study: the Trail Making Test – Parts A and B 
(TMT-AB), the Wechsler Memory Scale (WMS-III), the Stroop Colour and Word 
Test  (Stroop test) and the Digit Span Test (DST). These instruments are commonly 
included in neuropsychological test batteries and would be expected to be identified 
in this review.  
 
Olson et al., [14] identified that no screening tools were suitable for application in a 
clinical situation in the 2011 review. This review differed in that it identified four 
potential assessment tools with valid psychometric properties that may be utilised in a 
clinical setting. These assessment tools included the FACT-COG [30], CSC-W21 
[33], the BTACT and the AFI. The FACT-Cog, CSC-W21 and AFI [50] were both 
examined on a cancer population, with the FACT-Cog and AFI being examined on a 
BC population specifically. The BTACT [43] focused on a ‘midlife’ population 
between the age ranges of 32 and 84 years old and results from study indicated good 
convergent correlations with gold standard cognitive tests administered in person and 
may be more sensitive than cognitive tests used to screen for dementia [43]. However 
this claim was not supported by adequate evidence regarding specificity and 
sensitivity, and it is unknown whether these assessment tools would translate 
effectively to be used to assess the CRCC experienced by breast cancer patients. 
 
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 	
	
56
Olson et al., (2016) made note that many authors have reported a concern about the 
lack of congruence between perceived cognitive function and objective tests of 
cognitive function. However, the four assessment tools identified in this review that 
had the strongest psychometric properties all rely on subjective assessment. Objective 
assessments identified in this review did not have the same level of psychometric 
properties as the four assessments identified. This observation raises questions 
regarding the use of objective testing in a population that experiences symptom 
clusters, as well as CRCC still being questioned for its pathological existence.  This 
challenges how health practitioners should approach CRCC when presented with a 
client who has these experiences.  
 
Quality of Papers and Impact on Clinical Utility  
To practice in an evidence-based way, the assessment of the quality of research 
papers is critical prior to implementing techniques into clinical practice [54]. The 
critical analysis of the review studies revealed weaknesses in five specific areas. 
While some studies were not focused on psychometric properties, other studies also 
had consistent weaknesses related to considering specific psychometric properties, 
using an appropriate sample size, looking at a range of psychometric properties, 
participant retention and follow-up and using more analyses to explore the point 
estimates identified.   
 
Weaknesses in these areas reduce the strength of the evidence to support the use of 
assessment tools that may be relevant to the BC population. Terwee et al., [27] 
highlights the importance of defining the population of interest when undergoing 
studies regarding the quality of psychometric properties, as differences can occur in 
measurement properties between populations and settings. This was a problem that 
was also encountered in Olson et al.,[14], who found inconsistencies across the 
instruments selected, study design, sample characteristics and the stage of the disease. 
Our results support Olson’s findings that sample size, appropriate consideration of 
subjective versus objective assessments (and, from findings from this research, 
consideration of psychometric properties) were inadequate to support the quality of 
studies.  
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The group of studies that examined the existence of CRCC rather than examining the 
psychometric properties of particular assessment tools (Group C) became a point of 
interest for the study. Out of the ten assessment tools identified in these studies that 
were relevant to the cognitive domains affected in breast cancer patients, six of them 
were not supported by adequate reference material for the population of interest. 
However, four of these tests (TMT-AB; WMS-III; Stroop Test; DST) are used 
commonly in neuropsychological test batteries, which is an issue to be addressed for 
their continued used in the breast cancer population.  
 
Overall, these issues may impact on the confidence of health practitioners when 
selecting an assessment tool to use for CRCC with the BC population.   
 
The objective vs. subjective debate: fMRI and ecological instruments 
A number of studies discussed the use of fMRI within the article and two studies used 
fMRI as an assessment instrument [28, 55]. fMRI remains one of the only reliable 
assessment instruments to determine the pathological existence of CRCC. However, 
as a purely objective measure it cannot provide any information about the experience 
of CRCC or the effect of CRCC on functional activities such as work, without the 
support of subjective assessment tools or neuropsychological test batteries. Yet, it is 
one of the few assessment methods that can be administered without bias, to validate 
the individual experience of CRCC. Other disadvantages of this assessment method 
relate to the skills of health professionals in conducting fMRIs, the availability of the 
technology and the cost of conducting fMRIs. 
 
Some research evidence suggests that there is a poor association between objective 
and subjective measures of CRCC. This may be related to the variety of definitions, 
assessment items and cut off scores utilised in studies assessing CRCC [56]. One 
interesting approach discussed in a number of studies was that assessment tools 
should have ecological validity – i.e assessment tasks should be related to real-world 
tasks [13, 41, 57, 58]. This would then translate to how a person functions in their 
environment and according their capabilities. This notion of ecologically valid 
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assessment is in line with the results from this review, where three of the four 
assessment tools identified with the most appropriate psychometric properties were 
not only subjective instruments but also contained ecologically valid components to 
determine the impact of CRCC on an individual’s functioning [28, 30, 33].  
 
The final four instruments: a summary 
The FACT-COG is a self-reported questionnaire (subjective instrument) that 
evaluates perceived cognitive abilities, and the effect of CRCC on health related 
quality of life. Its main focus is on the functional effects of multiple specific cognitive 
domains, including memory, verbal ability, concentration, mental acuity and 
multitasking [30]. This includes three of the four cognitive domains identified as 
commonly affected in the breast cancer population, with the exception of processing 
speed. Williams [59] provided no information on the FACT-Cog in relation to floor-
ceiling effects, sensitivity and specificity.  
 
The CSC-W21 is also a self-report questionnaire (subjective instrument) that is 
directed at the breast cancer population returning to work [33]. It has a strong 
ecological element in that its questions are directed at work tasks and work 
functioning. It is structured around the cognitive domains of working memory and 
executive functioning. Dorland [33] provided no information on criterion validity, 
sensitivity or specificity. However, it was the only study out of the four identified to 
address potential floor or ceiling effects.  
 
The AFI is a self-report instrument that measures subjective perceptions of 
‘effectiveness’ in cognitive function in daily life [28]. Its main focus is on the 
cognitive domains of attention and working memory. The analysis by Cimprich [50] 
lacked information on criterion validity, floor-ceiling effects, and sensitivity or 
specificity properties.  
 
These three instruments are potential instruments that could be utilised by clinicians. 
However, as CRCC is the population of interest, more information is needed in future 
studies regarding floor and ceiling effects, sensitivity and specificity. The cognitive 
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domain of processing speed was not included in these instruments. While it is 
recognised that cognitive domains associated with the pre-frontal cortex all function 
in an integrated way to produce a result, processing speed should be specifically 
addressed as it is identified as an individual process within the literature [3, 13, 23, 
24]. 
 
The BTACT was the only study from group C with relatively sound psychometric 
properties that was potentially appropriate for the BC population. It was developed to 
address the need for reliable and valid testing of cognition in survey work with 
community-based samples [43]. Its strength is that it was deemed possible to identify 
MCI in adults of different age ranges. While its focus is on cognitive function in 
relation to aging, it is a tool that with refinement may have the ability to be used in 
clinical samples for MCI associated with other causes other than the aging process, 
such as CRCC and results may be more nuanced and accurate if implemented in face-
to-face testing [43]. The BTACT also offered the only objective method of potential 
testing relevant to the CRCC population, with strong psychometric properties 
identified. Cognitive domains identified in the BTACT were memory, reasoning, 
verbal fluency and executive functioning. However, one major flaw of the BTACT 
was the indeterminate rating given for reliability. As this is a critical psychometric 
property it may not be considered an evidence-based option for health practitioners. 
There was also limited information available about floor and ceiling effects, 
sensitivity or specificity.  
 
Limitations  
One of the major limitations of this review was the difficulty inherent in the lack of 
consistency in the definitions of cognitive domains provided by the studies. This 
made the selection of appropriate search terms difficult in the initial screening 
process. The population of interest further complicated the review, as while the 
specific cognitive domains specific to the breast cancer population were identified, by 
limiting the population to breast cancer, some relevant studies may have been missed.  
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Conclusion 
 
The purpose of this review was to replicate the review of potential assessment 
instruments to be used for identifying CRCC completed by Olson et al., [14]. This 
study advanced on this review by focusing on breast cancer as the population and 
assessing the psychometric properties of potential instruments for detecting CRCC. 
This review has contributed to the ongoing search for assessment instruments that can 
identify CRCC for the cancer population. By focusing the population on studies 
related to breast cancer, and the four specific cognitive domains commonly affected in 
the breast cancer population, the search could be narrowed and an in-depth critical 
appraisal was conducted. The Terwee analysis highlighted major issues with studies 
attempting to assess CRCC or MCI, including definition of the population, 
consideration of psychometric properties vital to the identification of CRCC (i.e. 
sensitivity, specificity, floor-ceiling effects, reliability and validity), the need for more 
longitudinal studies and appropriate analyses. Future research would benefit from 
addressing these issues highlighted above and focusing on the identified psychometric 
properties in order to understand the assessment tools at a high quality for evidence-
based practice.  
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Dissertation
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If you are unsure, please use the full journal title.
For authors using EndNote, Springer provides an output style that supports the formatting of in-
text citations and reference list.
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included
in Springer’s LaTeX macro package.
TABLES
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the
table.
Identify any previously published material by giving the original source in the form of
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Footnotes to tables should be indicated by superscript lower-case letters (or
asterisks for significance values and other statistical data) and included beneath the
table body.
ARTWORK AND ILLUSTRATIONS GUIDELINES
Electronic Figure Submission
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.
For vector graphics, the preferred format is EPS; for halftones, please use TIFF
format. MSOffice files are also acceptable.
Vector graphics containing fonts must have the fonts embedded in the files.
Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
Definition: Black and white graphic with no shading.
Do not use faint lines and/or lettering and check that all lines and lettering within the
figures are legible at final size.
All lines should be at least 0.1 mm (0.3 pt) wide.
Scanned line drawings and line drawings in bitmap format should have a minimum
resolution of 1200 dpi.
Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
Definition: Photographs, drawings, or paintings with fine shading, etc.
If any magnification is used in the photographs, indicate this by using scale bars
within the figures themselves.
Halftones should have a minimum resolution of 300 dpi.
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Combination Art
Definition: a combination of halftone and line art, e.g., halftones containing line
drawing, extensive lettering, color diagrams, etc.
Combination artwork should have a minimum resolution of 600 dpi.
Color Art
Color art is free of charge for online publication.
If black and white will be shown in the print version, make sure that the main
information will still be visible. Many colors are not distinguishable from one another
when converted to black and white. A simple way to check this is to make a
xerographic copy to see if the necessary distinctions between the different colors are
still apparent.
If the figures will be printed in black and white, do not refer to color in the captions.
Color illustrations should be submitted as RGB (8 bits per channel).
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Figure Lettering
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
Keep lettering consistently sized throughout your final-sized artwork, usually about
2–3 mm (8–12 pt).
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt
type on an axis and 20-pt type for the axis label.
Avoid effects such as shading, outline letters, etc.
Do not include titles or captions within your illustrations.
Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.).
If an appendix appears in your article and it contains one or more figures, continue
the consecutive numbering of the main text. Do not number the appendix figures,
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material)
should, however, be numbered separately.
Figure Captions
Each figure should have a concise caption describing accurately what the figure
depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number,
also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be
placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles,
etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a
reference citation at the end of the figure caption.
Figure Placement and Size
Figures should be submitted separately from the text, if possible.
When preparing your figures, size figures to fit in the column width.
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide
and not higher than 234 mm.
For books and book-sized journals, the figures should be 80 mm or 122 mm wide
and not higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain permission
from the copyright owner(s) for both the print and online format. Please be aware that some
publishers do not grant electronic rights for free and that Springer will not be able to refund any
costs that may have occurred to receive these permissions. In such cases, material from other
sources should be used.
Accessibility
In order to give people of all abilities and disabilities access to the content of your figures,
please make sure that
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All figures have descriptive captions (blind users could then use a text-to-speech
software or a text-to-Braille hardware)
Patterns are used instead of or in addition to colors for conveying information
(colorblind users would then be able to distinguish the visual elements)
Any figure lettering has a contrast ratio of at least 4.5:1
ELECTRONIC SUPPLEMENTARY MATERIAL
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other
supplementary files to be published online along with an article or a book chapter. This feature
can add dimension to the author's article, as certain information cannot be printed or is more
convenient in electronic form.
Before submitting research datasets as electronic supplementary material, authors should read
the journal’s Research data policy. We encourage research data to be archived in data
repositories wherever possible.
Submission
Supply all supplementary material in standard file formats.
Please include in each file the following information: article title, journal name, author
names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may
require very long download times and that some users may experience other
problems during downloading.
Audio, Video, and Animations
Aspect ratio: 16:9 or 4:3
Maximum file size: 25 GB
Minimum video duration: 1 sec
Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts,
m4v, 3gp
Text and Presentations
Submit your material in PDF format; .doc or .ppt files are not suitable for long-term
viability.
A collection of figures may also be combined in a PDF file.
Spreadsheets
Spreadsheets should be converted to PDF if no interaction with the data is intended.
If the readers should be encouraged to make their own calculations, spreadsheets
should be submitted as .xls files (MS Excel).
Specialized Formats
Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica
notebook), and .tex can also be supplied.
Collecting Multiple Files
It is possible to collect multiple files in a .zip or .gz file.
Numbering
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If supplying any supplementary material, the text must make specific mention of the
material as a citation, similar to that of figures and tables.
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the
animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.
Captions
For each supplementary material, please supply a concise caption describing the
content of the file.
Processing of supplementary files
Electronic supplementary material will be published as received from the author
without any conversion, editing, or reformatting.
Accessibility
In order to give people of all abilities and disabilities access to the content of your
supplementary files, please make sure that
The manuscript contains a descriptive caption for each supplementary material
Video files do not contain anything that flashes more than three times per second (so
that users prone to seizures caused by such effects are not put at risk)
ENGLISH LANGUAGE SUPPORT
For editors and reviewers to accurately assess the work presented in your manuscript you need
to ensure the English language is of sufficient quality to be understood. If you need help with
writing in English you should consider:
Asking a colleague who is a native English speaker to review your manuscript for
clarity.
Visiting the English language tutorial which covers the common mistakes when
writing in English.
Using a professional language editing service where editors will improve the English
to ensure that your meaning is clear and identify problems that require your review.
Two such services are provided by our affiliates Nature Research Editing Service
and American Journal Experts.
English language tutorial
Nature Research Editing Service
American Journal Experts
Please note that the use of a language editing service is not a requirement for publication in this
journal and does not imply or guarantee that the article will be selected for peer review or
accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style
before publication.
AFTER ACCEPTANCE
Upon acceptance of your article you will receive a link to the special Author Query Application at
Springer’s web page where you can sign the Copyright Transfer Statement online and indicate
whether you wish to order OpenChoice and offprints.
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Once the Author Query Application has been completed, your article will be processed and you
will receive the proofs.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Publication of color illustrations is free of charge.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness
and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results,
corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will
be hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first
publication citable with the DOI. After release of the printed version, the paper can also be cited
by issue and page numbers.
OPEN CHOICE
In addition to the normal publication process (whereby an article is submitted to the journal and
access to that article is granted to customers who have purchased a subscription), Springer
provides an alternative publishing option: Springer Open Choice. A Springer Open Choice
article receives all the benefits of a regular subscription-based article, but in addition is made
available publicly through Springer’s online platform SpringerLink.
Open Choice
Copyright and license term – CC BY-NC
Open Choice articles do not require transfer of copyright as the copyright remains with the
author. In opting for open access, the author(s) agree to publish the article under the Creative
Commons Attribution-NonCommercial 4.0 International License
Find more about the license agreement
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher
exclusive publication and dissemination rights). This will ensure the widest possible protection
and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the
author. In opting for open access, the author(s) agree to publish the article under the Creative
Commons Attribution Noncommercial License.
ETHICAL RESPONSIBILITIES OF AUTHORS
This journal is committed to upholding the integrity of the scientific record. As a member of the
Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to
deal with potential acts of misconduct.
Authors should refrain from misrepresenting research results which could damage the trust in
the journal, the professionalism of scientific authorship, and ultimately the entire scientific
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endeavour. Maintaining integrity of the research and its presentation can be achieved by
following the rules of good scientific practice, which include:
The manuscript has not been submitted to more than one journal for simultaneous
consideration.
The manuscript has not been published previously (partly or in full), unless the new
work concerns an expansion of previous work (please provide transparency on the
re-use of material to avoid the hint of text-recycling (“self-plagiarism”)).
A single study is not split up into several parts to increase the quantity of
submissions and submitted to various journals or to one journal over time (e.g.
“salami-publishing”).
No data have been fabricated or manipulated (including images) to support your
conclusions
No data, text, or theories by others are presented as if they were the author’s own
(“plagiarism”). Proper acknowledgements to other works must be given (this includes
material that is closely copied (near verbatim), summarized and/or paraphrased),
quotation marks are used for verbatim copying of material, and permissions are
secured for material that is copyrighted.
Important note: the journal may use software to screen for plagiarism.
Consent to submit has been received explicitly from all co-authors, as well as from
the responsible authorities - tacitly or explicitly - at the institute/organization where
the work has been carried out, before the work is submitted.
Authors whose names appear on the submission have contributed sufficiently to the
scientific work and therefore share collective responsibility and accountability for the
results.
In addition:
Changes of authorship or in the order of authors are not accepted after acceptance
of a manuscript.
Requesting to add or delete authors at revision stage, proof stage, or after
publication is a serious matter and may be considered when justifiably warranted.
Justification for changes in authorship must be compelling and may be considered
only after receipt of written approval from all authors and a convincing, detailed
explanation about the role/deletion of the new/deleted author. In case of changes at
revision stage, a letter must accompany the revised manuscript. In case of changes
after acceptance or publication, the request and documentation must be sent via the
Publisher to the Editor-in-Chief. In all cases, further documentation may be required
to support your request. The decision on accepting the change rests with the Editor-
in-Chief of the journal and may be turned down. Therefore authors are strongly
advised to ensure the correct author group, corresponding author, and order of
authors at submission.
Upon request authors should be prepared to send relevant documentation or data in
order to verify the validity of the results. This could be in the form of raw data,
samples, records, etc.
If there is a suspicion of misconduct, the journal will carry out an investigation following the
COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the
accused author will be contacted and given an opportunity to address the issue. If misconduct
has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s
implementation of the following measures, including, but not limited to:
If the article is still under consideration, it may be rejected and returned to the author.
If the article has already been published online, depending on the nature and
severity of the infraction, either an erratum will be placed with the article or in severe
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cases complete retraction of the article will occur. The reason must be given in the
published erratum or retraction note.
The author’s institution may be informed.
COMPLIANCE WITH ETHICAL STANDARDS
To ensure objectivity and transparency in research and to ensure that accepted principles of
ethical and professional conduct have been followed, authors should include information
regarding sources of funding, potential conflicts of interest (financial or non-financial), informed
consent if the research involved human participants, and a statement on welfare of animals if
the research involved animals.
Authors should include the following statements (if applicable) in a separate section entitled
“Compliance with Ethical Standards” when submitting a paper:
Disclosure of potential conflicts of interest
Research involving Human Participants and/or Animals
Informed consent
Please note that standards could vary slightly per journal dependent on their peer review
policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before
submitting your article check the instructions following this section carefully.
The corresponding author should be prepared to collect documentation of compliance with
ethical standards and send if requested during peer review or after publication.
The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned
guidelines. The author will be held responsible for false statements or failure to fulfill the above-
mentioned guidelines.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
Authors must disclose all relationships or interests that could have direct or potential influence
or impart bias on the work. Although an author may not feel there is any conflict, disclosure of
relationships and interests provides a more complete and transparent process, leading to an
accurate and objective assessment of the work. Awareness of a real or perceived conflicts of
interest is a perspective to which the readers are entitled. This is not meant to imply that a
financial relationship with an organization that sponsored the research or compensation
received for consultancy work is inappropriate. Examples of potential conflicts of interests that
are directly or indirectly related to the research may include but are not limited to the
following:
Research grants from funding agencies (please give the research funder and the
grant number)
Honoraria for speaking at symposia
Financial support for attending symposia
Financial support for educational programs
Employment or consultation
Support from a project sponsor
Position on advisory board or board of directors or other type of management
relationships
Multiple affiliations
Financial relationships, for example equity ownership or investment interest
Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
Holdings of spouse and/or children that may have financial interest in the work
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 80
	
10/7/2016 Supportive Care in Cancer
http://www.springer.com/medicine/internal/journal/520?detailsPage=pltci_1060106 15/17
Disclosure form (pdf, 1.1 MB)
In addition, interests that go beyond financial interests and compensation (non-financial
interests) that may be important to readers should be disclosed. These may include but are not
limited to personal relationships or competing interests directly or indirectly tied to this research,
or professional interests or personal beliefs that may influence your research.
The corresponding author collects the conflict of interest disclosure forms from all authors. In
author collaborations where formal agreements for representation allow it, it is sufficient for the
corresponding author to sign the disclosure form on behalf of all authors. The ICMJE form can
be found below:
Please open the disclosure form with Internet Explorer or Firefox.
RESEARCH INVOLVING HUMAN PARTICIPANTS AND/OR ANIMALS
1) Statement of human rights
When reporting studies that involve human participants, authors should include a statement that
the studies have been approved by the appropriate institutional and/or national research ethics
committee and have been performed in accordance with the ethical standards as laid down in
the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
If doubt exists whether the research was conducted in accordance with the 1964 Helsinki
Declaration or comparable standards, the authors must explain the reasons for their approach,
and demonstrate that the independent ethics committee or institutional review board explicitly
approved the doubtful aspects of the study.
The following statements should be included in the text before the References section:
Ethical approval: “All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments or comparable ethical
standards.”
For retrospective studies, please add the following sentence:
“For this type of study formal consent is not required.”
2) Statement on the welfare of animals
The welfare of animals used for research must be respected. When reporting experiments on
animals, authors should indicate whether the international, national, and/or institutional
guidelines for the care and use of animals have been followed, and that the studies have been
approved by a research ethics committee at the institution or practice at which the studies were
conducted (where such a committee exists).
For studies with animals, the following statement should be included in the text before the
References section:
Ethical approval: “All applicable international, national, and/or institutional guidelines for the
care and use of animals were followed.”
If applicable (where such a committee exists): “All procedures performed in studies involving
animals were in accordance with the ethical standards of the institution or practice at which the
studies were conducted.”
If articles do not contain studies with human participants or animals by any of the authors,
please select one of the following statements:
“This article does not contain any studies with human participants performed by any of the
authors.”
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“This article does not contain any studies with animals performed by any of the authors.”
“This article does not contain any studies with human participants or animals performed by any
of the authors.”
INFORMED CONSENT
All individuals have individual rights that are not to be infringed. Individual participants in studies
have, for example, the right to decide what happens to the (identifiable) personal data gathered,
to what they have said during a study or an interview, as well as to any photograph that was
taken. Hence it is important that all participants gave their informed consent in writing prior to
inclusion in the study. Identifying details (names, dates of birth, identity numbers and other
information) of the participants that were studied should not be published in written descriptions,
photographs, and genetic profiles unless the information is essential for scientific purposes and
the participant (or parent or guardian if the participant is incapable) gave written informed
consent for publication. Complete anonymity is difficult to achieve in some cases, and informed
consent should be obtained if there is any doubt. For example, masking the eye region in
photographs of participants is inadequate protection of anonymity. If identifying characteristics
are altered to protect anonymity, such as in genetic profiles, authors should provide assurance
that alterations do not distort scientific meaning.
The following statement should be included:
Informed consent: “Informed consent was obtained from all individual participants included in
the study.”
If identifying information about participants is available in the article, the following statement
should be included:
“Additional informed consent was obtained from all individual participants for whom identifying
information is included in this article.”
2015 Impact Factor 2.535
READ THIS JOURNAL ON SPRINGERLINK
FOR AUTHORS AND EDITORS
SERVICES FOR THE JOURNAL
View Open Access Articles
Online First Articles
All Volumes & Issues
Aims and Scope
Submit Online
Open Choice - Your Way to Open Access
Instructions for Authors
COI Form (open with Internet Explorer or...
Contacts
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 82
		
	
	
	
10/7/2016 Supportive Care in Cancer
http://www.springer.com/medicine/internal/journal/520?detailsPage=pltci_1060106 17/17
ALERTS FOR THIS JOURNAL
Get the table of contents of every new issue published in
Supportive Care in Cancer.
Please send me information on new Springer
publications in Oncology .
ADDITIONAL INFORMATION
RELATED BOOKS - SERIES - JOURNALS
Book
The MASCC Textbook
of Cancer Supportive
Care and Survivorship
Editor» Olver, Ian (Ed.)
Download Product Flyer
Shipping Dates
Order Back Issues
Bulk Orders
Ad Rate Card (pdf, 553 kB)
Pharma Reprints
SUBMIT
MASCC/ISOO 2017 Annual Meeting (pdf, 1.0...
BACK  NEXT 1/10
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 83
Appendix II: Critical Appraisal of Study Design for Psychometric Articles  
Evaluation	Form	
	
		
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 84
	
	
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 85
	
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 86
HSBH5006: Research Elective Dissertation 
 
	
	
Hannah	Nunn		
SID:	450	382	309	 87
	
	
Appendix III: Quality Criteria for Measurement Properties of Health Status 
Questionnaires (Terwee, et al., 2007) 
	
